Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. Show more
Location: 1500 District Avenue, Burlington, MA, 01803, United States | Website: https://www.minervaneurosciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
12.03M
52 Wk Range
$1.15 - $3.50
Previous Close
$1.72
Open
$1.68
Volume
10,306
Day Range
$1.57 - $1.75
Enterprise Value
54.74M
Cash
17.29M
Avg Qtr Burn
-4.382M
Insider Ownership
22.26%
Institutional Own.
28.10%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Roluperidone (5-HT2A antagonist) Details Central nervous system illness, Mental health, Schizophrenia | NDA Resubmission | |
Seltorexant (Orexin2 antagonist) Details Insomnia, Mood disorders | Failed Discontinued |